Search by Drug Name or NDC
NDC 00574-0147-04 famotidine 40 mg/5mL Details
famotidine 40 mg/5mL
famotidine is a ORAL POWDER, FOR SUSPENSION in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Padagis US LLC. The primary component is FAMOTIDINE.
MedlinePlus Drug Summary
Famotidine injection is used in people who are hospitalized to treat certain conditions in which the stomach produces too much acid or to treat ulcers (sores in the lining of the stomach or intestine) that were not successfully treated with other medications. Famotidine injection is also used on a short-term basis in people who cannot take oral medication to treat ulcers, to prevent ulcers from returning after they have healed, to treat gastroesophageal reflux disease (GERD, a condition in which backward flow of acid from the stomach causes heartburn and injury of the esophagus [tube between the throat and the stomach]), and to treat conditions where the stomach produces too much acid, such as Zollinger-Ellison syndrome (tumors in the pancreas and small intestine that caused increased production of stomach acid). Famotidine injection is in a class of medications called H2 blockers. It works by decreasing the amount of acid made in the stomach.
Related Packages: 00574-0147-04Last Updated: 03/24/2024
MedLinePlus Full Drug Details: Famotidine Injection
Product Information
| NDC | 00574-0147 |
|---|---|
| Product ID | 0574-0147_833284dd-bd16-444c-a965-6f70359fc19d |
| Associated GPIs | |
| GCN Sequence Number | n/a |
| GCN Sequence Number Description | n/a |
| HIC3 | n/a |
| HIC3 Description | n/a |
| GCN | n/a |
| HICL Sequence Number | n/a |
| HICL Sequence Number Description | n/a |
| Brand/Generic | n/a |
| Proprietary Name | famotidine |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | famotidine |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | POWDER, FOR SUSPENSION |
| Route | ORAL |
| Active Ingredient Strength | 40 |
| Active Ingredient Units | mg/5mL |
| Substance Name | FAMOTIDINE |
| Labeler Name | Padagis US LLC |
| Pharmaceutical Class | Histamine H2 Receptor Antagonists [MoA], Histamine-2 Receptor Antagonist [EPC] |
| DEA Schedule | n/a |
| Marketing Category | NDA AUTHORIZED GENERIC |
| Application Number | NDA019527 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 00574-0147-04 (00574014704)
| NDC Package Code | 0574-0147-04 |
|---|---|
| Billing NDC | 00574014704 |
| Package | 50 mL in 1 BOTTLE (0574-0147-04) |
| Marketing Start Date | 2010-05-28 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |